Testing iberdomide with therapy for neuroblastoma that has returned or not responded
Treatments studied
Part of Cancer clinical trials.
This trial tests adding a new drug called iberdomide to standard treatment for children and young adults with neuroblastoma that has returned or not responded. The goal is to see if it helps control the cancer better than usual therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 30 years old.
- You must have neuroblastoma that has come back, did not respond to treatment, or got worse.
- You must have visible disease on a MIBG or PET scan (not just bone marrow or urine markers).
- You must have had no more than one prior chemoimmunotherapy (chemotherapy combined with anti-GD2 antibody) regimen.
- You must have had no more than two prior lines of therapy in total.
- Your kidneys, liver, blood counts, and heart must be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests a combination of targeted radiation (MIBG) with two medicines, vorinostat and dinutuximab, for children and young adults with high-risk neuroblastoma that has returned or not fully responded to earlier treatment. The goal is to see if adding these medicines helps the radiation work better and improves outcomes.
This trial gives a radioactive drug called 131-I-MIBG to treat neuroblastoma that has not gone away or has come back. The drug targets cancer cells, and stem cells are given back after treatment to help the body recover.
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
This trial uses a radioactive medicine called MIBG to target and kill neuroblastoma or related tumor cells that have not responded to standard treatments. It may help patients whose cancer has come back or is hard to treat.
Hear when a new Refractory Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.